This page has beta status

BMBS COST Action BM1003
Microbial cell surface determinants of virulence as targets for new therapeutics in Cystic Fibrosis

This COST Action relates to bacterial infections seen in the human hereditary disease Cystic Fibrosis (CF). This is the most common lethal single gene disorder in Europe and is associated with end organ inflammation and damage particularly affecting the lungs. The bacterial factors and the molecular mechanisms which provoke full blown inflammation in CF are mostly unclear. The COST Action will investigate the structure, function and immunostimulatory activity of CF pathogens including Gram negative and Gram positive cell wall components. These pathogens particularly Pseudomonas, Acinetobacter and S. aureus are also important causes of hospital acquired infections affecting many other patient groups thus improving made within this COST Action may have much wider applicability to include immunosuppressed or hospitalised patients who are also at risk from these bacteria.

(Descriptions are provided by the Actions directly via e-COST.)

General Information*

Chair of the Action:

Prof Antonio MOLINARO (IT)

Vice Chair of the Action:

Dr Anthony DE SOYZA (UK)

Science officer of the Action:


Administrative officer of the Action:

Ms Jeannette NCHUNG ORU


Action Fact Sheet

Download AFS as .RTF

Memorandum of Understanding

Download MoU as PDF

Progress Report

Download Progress Report as PDF


Download Poster as PDF


* content provided by e-COST.
Data is synchronised once per night.


Last updated: 02 May 2011 top of page